AU2006240561B2 - Methods and means for the treatment of HPV induced intraepithelial neoplasias - Google Patents

Methods and means for the treatment of HPV induced intraepithelial neoplasias Download PDF

Info

Publication number
AU2006240561B2
AU2006240561B2 AU2006240561A AU2006240561A AU2006240561B2 AU 2006240561 B2 AU2006240561 B2 AU 2006240561B2 AU 2006240561 A AU2006240561 A AU 2006240561A AU 2006240561 A AU2006240561 A AU 2006240561A AU 2006240561 B2 AU2006240561 B2 AU 2006240561B2
Authority
AU
Australia
Prior art keywords
hpv
use according
antigen
treatment
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006240561A
Other languages
English (en)
Other versions
AU2006240561A1 (en
Inventor
Theodorus Jozef Maria Helmerhorst
Cornelis Johannes Maria Melief
Rienk Offringa
Sjoerd Henricus Van Der Burg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leids Universitair Medisch Centrum LUMC
Original Assignee
Leids Universitair Medisch Centrum LUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leids Universitair Medisch Centrum LUMC filed Critical Leids Universitair Medisch Centrum LUMC
Publication of AU2006240561A1 publication Critical patent/AU2006240561A1/en
Application granted granted Critical
Publication of AU2006240561B2 publication Critical patent/AU2006240561B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2006240561A 2005-04-27 2006-04-25 Methods and means for the treatment of HPV induced intraepithelial neoplasias Ceased AU2006240561B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05103447.8 2005-04-27
EP05103447 2005-04-27
PCT/NL2006/050099 WO2006115413A2 (en) 2005-04-27 2006-04-25 Methods and means for the treatment of hpv induced intraepithelial neoplasias

Publications (2)

Publication Number Publication Date
AU2006240561A1 AU2006240561A1 (en) 2006-11-02
AU2006240561B2 true AU2006240561B2 (en) 2011-06-02

Family

ID=35583560

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006240561A Ceased AU2006240561B2 (en) 2005-04-27 2006-04-25 Methods and means for the treatment of HPV induced intraepithelial neoplasias

Country Status (10)

Country Link
US (2) US7807369B2 (https=)
EP (2) EP1874312B1 (https=)
JP (1) JP5106384B2 (https=)
CN (1) CN101189014A (https=)
AT (1) ATE506063T1 (https=)
AU (1) AU2006240561B2 (https=)
CA (1) CA2609927A1 (https=)
DE (1) DE602006021408D1 (https=)
ES (1) ES2363247T3 (https=)
WO (1) WO2006115413A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009012922A (es) * 2007-05-31 2010-07-05 Academisch Ziekenhuis Leiden H Vacunacion intradermica de un peptido del virus del papiloma humano.
CN102686720B (zh) * 2009-11-17 2013-12-04 国立大学法人冈山大学 由牙髓细胞向成牙本质细胞的分化诱导方法
EP2508190B1 (en) * 2009-12-03 2021-06-02 Aureo Co., Ltd. Macrophage phagocytosis-activating composition and/or composition promoting cytokine production in macrophages
US20150310003A1 (en) * 2014-04-28 2015-10-29 Elwha Llc Methods, systems, and devices for machines and machine states that manage relation data for modification of documents based on various corpora and/or modification data
WO2017015504A1 (en) * 2015-07-21 2017-01-26 Scheibel Steven Frederick Treatment and prevention of anal conditions
ES3055492T3 (en) 2015-09-16 2026-02-12 Dfb Soria Llc Delivery of drug nanoparticles and methods of use thereof
WO2017083963A1 (en) 2015-11-18 2017-05-26 Immunovaccine Technologies Inc. Adjuvanting systems and water-free vaccine compositions comprising a polyi:c polynucleotide adjuvant and a lipid-based adjuvant
CN106632694B (zh) * 2017-01-24 2021-02-12 南京益康生物医药有限公司 一种重组蛋白及药物组合物与应用
WO2018170196A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
WO2018170210A1 (en) * 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of vulvar intraepithelial neoplasia (vin) and genital warts using nanoparticles of taxanes
RU2682783C2 (ru) * 2017-06-14 2019-03-21 Федеральное государственное бюджетное учреждение "Уральский научно-исследовательский институт охраны материнства и младенчества" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ ОММ" Минздрава России) Способ лечения цервикальных интраэпителиальных неоплазий i степени, ассоциированных с впч высокого онкогенного риска, с использованием кавитированного раствора панавира
EP3765035A4 (en) 2018-03-16 2021-10-27 DFB Soria, LLC TOPICAL THERAPY FOR THE TREATMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) AND COLD CANCER USING TAXANE NANOPARTICLES
CN109614613B (zh) 2018-11-30 2020-07-31 北京市商汤科技开发有限公司 图像的描述语句定位方法及装置、电子设备和存储介质
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
CN111905201A (zh) * 2020-08-18 2020-11-10 珠海市索利达医疗器械有限公司 一种生殖道hr-hpv治疗设备
CN114409744B (zh) * 2022-03-29 2022-10-04 深圳吉诺因生物科技有限公司 Hpv抗原表位及其鉴定方法、应用
CN119529069B (zh) * 2025-01-22 2025-07-01 成都迈科康生物科技有限公司 一种抗hpv16和/或hpv18型e2蛋白的抗体、抗体偶联物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002070004A2 (en) * 2001-03-07 2002-09-12 Xenova Research Limited Papillomavirus vaccines
EP1288292A1 (en) * 2001-08-31 2003-03-05 Leids Universitair Medisch Centrum Long peptides of 22-40 amino acid residues that induce and/or enhance antigen specific immune responses.
WO2005020995A1 (en) * 2003-09-02 2005-03-10 3M Innovative Properties Company Methods related to the treatment of mucosal associated conditions
EP1140091B1 (en) * 1999-01-08 2005-09-21 3M Innovative Properties Company Formulations comprising imiquimod or other immune response modifiers for treating cervical dysplasia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ538399A (en) * 1997-08-05 2007-05-31 Nventa Biopharma Corp Fusion protein comprising an HPV E7 protein and a stress protein wherein the E7 protein is joined directly to the amino terminus of the stress protein
US20030118588A1 (en) 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
NZ523408A (en) * 2000-06-26 2006-02-24 Stressgen Biotechnologies Corp Human papilloma virus treatment
AU2002219711B8 (en) 2000-12-08 2006-03-02 Academisch Ziekenhuis Leiden Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
CA2467723C (en) * 2001-12-17 2011-09-27 Zymogenetics, Inc. Method for treating cervical cancer
EP1720567A2 (en) * 2004-02-10 2006-11-15 Innate Pharma Composition and method for the treatment of carcinoma

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1140091B1 (en) * 1999-01-08 2005-09-21 3M Innovative Properties Company Formulations comprising imiquimod or other immune response modifiers for treating cervical dysplasia
WO2002070004A2 (en) * 2001-03-07 2002-09-12 Xenova Research Limited Papillomavirus vaccines
EP1288292A1 (en) * 2001-08-31 2003-03-05 Leids Universitair Medisch Centrum Long peptides of 22-40 amino acid residues that induce and/or enhance antigen specific immune responses.
WO2005020995A1 (en) * 2003-09-02 2005-03-10 3M Innovative Properties Company Methods related to the treatment of mucosal associated conditions

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BURG VAN DER S H et al. INTERNATIONAL JOURNAL OF CANCER, 2001. Vol.91, no.5, pages 612-618 *
DE JONG et al. CANCER RESEARCH, 2002. Vol.62, no.2, pages 472-479 *
SAUDER, D. THE BRITISH JOURNAL OF DERMATOLOGY, 2003. Vol. 149 Suppl66, pages 5-8 *
STANLEY, M. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2002. Vol. 27, no.7, pages 571-577 *
TODD, R et al. GYNECOLOGIC ONCOLOGY, 2004. Vol. 92, no.1, pages 167-174 *

Also Published As

Publication number Publication date
US20090060870A1 (en) 2009-03-05
WO2006115413A2 (en) 2006-11-02
WO2006115413A3 (en) 2007-04-19
ES2363247T3 (es) 2011-07-28
AU2006240561A1 (en) 2006-11-02
JP2008539228A (ja) 2008-11-13
EP2289516B1 (en) 2014-01-08
US7807369B2 (en) 2010-10-05
EP1874312A2 (en) 2008-01-09
CN101189014A (zh) 2008-05-28
EP1874312B1 (en) 2011-04-20
ATE506063T1 (de) 2011-05-15
DE602006021408D1 (de) 2011-06-01
CA2609927A1 (en) 2006-11-02
EP2289516A1 (en) 2011-03-02
US20110008287A1 (en) 2011-01-13
JP5106384B2 (ja) 2012-12-26

Similar Documents

Publication Publication Date Title
US20110008287A1 (en) Methods and means for the treatment of hpv induced intraepithelial neoplasias
US11458198B2 (en) HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
Jee et al. Immunology of HPV-mediated cervical cancer: current understanding
van Poelgeest et al. Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment
EP2155240B1 (en) Intradermal hpv peptide vaccination
WO2007033533A1 (en) Use of nocardia rubra cell wall skeleton to produce medicaments for resisting human papilloma virus hpv
RU2377305C1 (ru) Мукозальная вакцина для иммунотерапии заболеваний, обусловленных вирусами папилломы человека, и способ лечения с ее использованием (варианты)
AU2013205259B2 (en) HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
van Poelgeest et al. 7 Detection of human papillomavirus (HPV) 16-specific CD4 with persistent HPV16-induced vulvar intraepithelial neoplasia
AU2017202609B2 (en) HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
HK40019593A (en) Hpv epitopes targeted by t cells infiltrating cervical malignancies for use in vaccines
Warren et al. Evasion of Host Immune Defenses by Human
Bourgault-Villada et al. Current Insight into Anti-HPV Immune Responses and Lessons for Prophylactic and Therapeutic Vaccines
Onon prophylactic vaccination

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired